Navigation Links
Quincy Bioscience Receives Patent for Jellyfish Protein Aequorin
Date:7/7/2010

Quincy Bioscience, a research-based biotechnology company, announced the issuance of United States patent No.7,671,015. The patent covers the use of aequorin-containing compounds for the purpose of preventing and alleviating symptoms and disorders related to calcium imbalance which include Alzheimer's disease.

Madison, Wis (Vocus) July 7, 2010 -- Quincy Bioscience, a research-based biotechnology company, announced the issuance of United States patent No.7,671,015. The patent covers the use of aequorin-containing compounds for the purpose of preventing and alleviating symptoms and disorders related to calcium imbalance.

“Quincy Bioscience continues to strengthen its position in developing this novel calcium-binding protein as a platform technology,” said Mark Underwood, president of Quincy Bioscience. “The neuron’s ability to manage calcium and maintain homeostasis is fundamental to proper function. Research has proven the cell’s inability to regulate calcium is a key pathophysiological component in many different brain disorders, including Alzheimer’s disease. Based on our ongoing research of aequorin in various health conditions and what we know about the role of calcium in the body, we expect aequorin to be a vital protein in many aspects of healthy aging.”

Aequorin, which comes from a species of jellyfish called Aequorea victoria, is a calcium-binding protein. In humans calcium-binding proteins are utilized to maintain calcium balance which is critical to proper cell function. Aequorin has proven to be neuroprotective in pre-clinical studies performed at the University of Wisconsin-Milwaukee and has shown to be effective at improving aspects of cognition such as spatial working memory and executive function in human studies conducted by Quincy Bioscience.

About Quincy Bioscience
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.

###

Read the full story at http://www.prweb.com/releases/2010/07/prweb4235874.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Quincy Bioscience Announces Encouraging Preliminary Results of Randomized, Double-Blind, Placebo-Controlled Memory Study
2. Quincy Bioscience Sponsors Multiple Sclerosis (MS) Scholarship Program
3. Quincy Bioscience Launches HOPETrials.com; Research Studies More Accessible For Participants
4. Flagship Biosciences Partners with a Leading IHC CLIA Laboratory for Companion Diagnostics Service
5. Martek Biosciences Chief Scientific Officer, Dr. Norman Salem, 2010 Recipient of Alex Leaf Distinguished Scientist Award
6. Martek Biosciences and the National Center for Creative Aging Introduce New Brain Health Awareness Campaign, "Beautiful Minds: Finding Your Lifelong Potential"
7. Exalenz Bioscience Expands Market Coverage for the BreathID Breath Test System
8. Digital Pathology Services Firm Flagship Biosciences Appoints New CEO
9. Southridge LLC Provides Equity Capital Through Private Agreement with PuraMed Bioscience
10. Childrens Hospital Los Angeles oncologist receives $50,000 Hyundai Scholar Award
11. Stamen Medical Systems Receives Medicare Re-Accreditation and The Exemplary Provider Award
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Quincy Bioscience Receives Patent for Jellyfish Protein Aequorin
(Date:4/28/2017)... ... April 28, 2017 , ... Christie Medical Holdings, Inc. , with its ... B. Braun Medical Inc. , a leader in infusion therapy and pain management. ... as 90 percent of hospital patients receiving a peripheral IV catheter as part of ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... Gasby the 2017 Public Leadership in Neurology Award (PLINA). The couple joins a ... Tedy Bruschi, Vice President Walter Mondale, actor Michael J. Fox and former U.S. ...
(Date:4/27/2017)... ... , ... Are you investing in the safety of your friends and family? ... summer. While most of us assume this type of accident will never happen to ... are taking the time to learn how to respond effectively or prevent these accidents ...
(Date:4/26/2017)... , ... April 26, 2017 ... ... is thrilled to announce the ATA 2017 President’s Awards recipients, comprised of ... demonstrated superior healthcare delivery. , The ATA 2017 President’s Awards recognize ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may ... pelvic conditions and has helped many women become pregnant upon treating their diagnosis. ... office-based and simple outpatient evaluations. We can provide the necessary information to ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market by Manufacturers, ... and analysed the potential of Global Effective Microorganisms (EM) Market ... growth factors. The report identifies and analyses the emerging trends ... market. ... and Figures, 6 Major Company Profiles, spread across 124 pages ...
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
(Date:4/18/2017)... -- Viverae ® , a leader in workplace wellness ... ® Watson Campaign Automation, implementing behavioral messaging within ... personalized experience. Through digital engagement, the platform prompts members ... time. The enhanced experience drives engagement by focusing on ... are in their journey to health. ...
Breaking Medicine Technology: